About: Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Host-directed therapies for infectious diseases: current status, recent progress, and future prospects Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Creator	Ippolito, Giuseppe Mwaba, Peter Zumla, Alimuddin Maeurer, Markus Azhar, Esam Chakaya, Jeremiah Hoelscher, Michael Rao, Martin Rustomjee, Roxana Vilaplana, Cris Yeboah-Manu, Dorothy Kaufmann, Stefan Wallis, Robert
Source	Elsevier; Medline; PMC
abstract	Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen–host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.
has issue date	2016-03-21(xsd:dateTime)
bibo:doi	10.1016/s1473-3099(16)00078-5
bibo:pmid	27036359
has license	no-cc
sha1sum (hex)	89021d6f522c58e68f3a401b215711f22084fe0c
schema:url	https://doi.org/10.1016/s1473-3099%2816%2900078-5
resource representing a document's title	Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
has PubMed Central identifier	PMC7164794
has PubMed identifier	27036359
schema:publication	Lancet Infect Dis
resource representing a document's body	covid:89021d6f522c58e68f3a401b215711f22084fe0c#body_text
is schema:about of	named entity 'Ebola virus' named entity 'Ebola virus' named entity 'RANTES' named entity 'Title' named entity 'PRO-' named entity 'CXCL10' named entity 'TNF-' named entity 'P38 MAPK' named entity 'EXPERIMENTAL' named entity 'production' named entity 'imidazole' named entity 'pro-inflammatory cytokines' named entity 'dendritic cells' named entity 'IL-12' named entity 'Host-Directed' named entity 'gentamicin' named entity 'cocci' named entity 'NRP1' named entity 'NRP1' named entity 'immune suppression' named entity 'septic shock' named entity 'plexins' named entity 'p38 MAPK' named entity 'developing countries' named entity 'Influenza virus' named entity 'VEGFR' named entity 'aryl hydrocarbon receptor' named entity 'Blastocystis' named entity 'antigen' named entity 'preclinical' named entity 'pathology' named entity 'NRP1' named entity 'sialic acid' named entity 'solid tumours' named entity 'GBS' named entity 'p38 MAPK' named entity 'infection' named entity 'SK1' named entity 'influenza' named entity 'host cells' named entity 'SB203580' named entity 'neutrophil' named entity 'thromboxane' named entity 'pharmacological' named entity 'SBAs' named entity 'receptor' named entity 'TGF-β1' named entity 'atorvastatin' named entity 'exogenous' named entity 'Pharmacological' named entity 'control patients' named entity 'MAPK' named entity 'MAPK' named entity 'Tregs' named entity 'IL-1β' named entity 'SIRS' named entity 'mice' named entity 'syncytia' named entity 'High levels' named entity 'biological processes' named entity 'physiological' named entity 'recombinant antibodies' named entity 'prostaglandin' named entity 'IL-1β' named entity 'IL-6' named entity 'ESAT-6' named entity 'infection' named entity 'Clostridium tetani' named entity 'PD-1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software